SIGA said it is focused on manufacturing and developing medicines for infectious diseases, with a primary focus on orthopoxviruses, and highlighted TPOXX as its main product. The company reported more than USD 1 billion in procurement contracts over more than 10 years working with governments, and said its products have been sold in more than 30 countries. SIGA said it realized about USD 680 million in product revenue and about USD 395 million in cumulative pre-tax operating income over the 2020–2025 period. The presentation listed Diem Nguyen as chief executive officer and Dan Luckshire as chief financial officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SIGA Technologies Inc. published the original content used to generate this news brief on March 11, 2026, and is solely responsible for the information contained therein.